Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 2012 /
Clinical trials and drug developments in pancreatic cancer

28th Sep - 2nd Oct 2012

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 09.10.12
Views: 3319

Dr Roberto Labianca – Ospedali Riuniti Bergamo, Italy

Dr Roberto Labianca talks to ecancer at the 2012 ESMO meeting in Vienna about the difficulty in treating pancreatic cancer and immerging therapies.


Nearly all patients with pancreatic cancer die from the disease within a small timeframe after diagnosis.  Only 20% of all patients can be resected, therefore most receive radiotherapy. Even with these treatments, the results are very limited.


Dr Labianca highlights new treatment options that are emerging with promising results. Currently, nab paclitaxel is offered to patients and studied in a number of clinical trials. There are ongoing trials with nab paclitaxel such as a promising phase I-II trial, and a phase III comparing standard treatment with nab paclitaxel plus standard treatment.


In addition, numerous biological studies are taking place in order to open up new targets for potential biological treatments.


Filming supported by Amgen

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation